March 1, 2017
Astellas Pharma and Affinivax said on February 28 that they have struck an exclusive worldwide license deal to develop and commercialize a vaccine targeting pneumococcus, developed based on the US firm’s proprietary Multiple Antigen Presenting System (MAPS) platform. Under the...read more